

CROATIAN JOURNAL OF ONCOLOGY

LIBRI ONCOLOGICI



LIBRI ONCOL. ISSN 0300-8142
UDK 616 – 006

2025 Vol. 53 Suppl. 2

VOLUMEN 53

NUMERUS suppl 2

LIBRI ONCOLOGICI

CROATIAN JOURNAL OF ONCOLOGY

Zagreb, 2025

CROATIAN JOURNAL OF ONCOLOGY
LIBRI ONCOLOGICI

Publisher

Sestre milosrdnice University Hospital Center
University Hospital for Tumors, Zagreb, Croatia

Editor-in-Chief

Ivan Milas

Editors

Lidija Beketić-Orešković, Antonio Juretić, Božena Šarčević

Associate Editors

Iva Kirac – Experimental Research
Mladen Stanec – Surgical Oncology
Robert Šeparović – Medical Oncology
Martina Mikulandra – Radiation Oncology

Technical Editor

Anica Vrdoljak

Editorial Board

Gordana Brozović, Sanda Bubanović, Željko Herceg, Ljiljana Mayer, Aleksandar Milenović, Melita Perić Balja, Mario Puljiz, Snježana Ramić, Vesna Ramljak, Andrej Roth, Danko Velimir Vrdoljak, Tiha Vučemilo

Editorial Council

M. Ćorić (Zagreb, Croatia), T. Čufer (Ljubljana, Slovenia), N. Đaković (Zagreb, Croatia), M. Gamulin (Zagreb, Croatia), D. Kalafatić (Zagreb, Croatia), S. Kaštelan (Zagreb, Croatia), Ž. Kaštelan (Zagreb, Croatia), M. Klarica (Zagreb, Croatia), D. Krleža (Dublin, Ireland), J. Koeva-Balabanova (Sofia, Bulgaria), D. La Forgia (Bari, Italy), A. Lancia (Pavia, Italy), D. Marčinko (Zagreb, Croatia), A. Mrkonjić (Malmö, Sweden), S. Orešković (Zagreb, Croatia), P. Ozretić (Zagreb, Croatia), S.Ž. Pavletić (Bethesda, USA), I. Tomaš (Osijek, Croatia), D. Vagić (Zagreb, Croatia), E. Vrdoljak (Split, Croatia), Ž. Vujašković (Baltimore, USA)

This journal is indexed or abstracted by:
SCOPUS, DOAJ, HRČAK, Scilit Basel, CrossReff, Index Copernicus, Google Scholar,
ResearchGate, JournalsPedia

Editorial Office:

LIBRI ONCOLOGICI, Ilica 197, 10 000 Zagreb, Croatia

Phone (385 1) 37 83 522

Web site: <http://hrcak.srce.hr/libri-oncologici>

e-mail: libri.oncologici@kbcsm.hr

The journal is published three times a year. Orders can be placed directly to the Editorial Office.

Price per copy 10 €. Annual subscription rates in Croatia: 45 € + VAT for institutions, 21 € + VAT for individuals and 10 € + VAT for students, to be remitted with Hrvatska narodna banka, account HR12 1001 0051 8630 0016 0 Ref.No.HR65 7129-051-26395 (for LIBRI ONCOLOGICI).

Annual subscription abroad - equivalent of US\$ 50 to be paid into the foreign currency account with Hrvatska narodna banka, IBAN: HR12 1001 0051 8630 0016 0 (Ref.No.HR65 7129-051-26395), BIC code: NBHRHR2XXXX (for LIBRI ONCOLOGICI)

Cover Design: Osman Berberović

Typesetting and printed by DENONA d.o.o., Zagreb

18.HOK

18. HRVATSKI ONKOLOŠKI KONGRES
27.-30.3.2025. | Hotel Lone | Rovinj



18. HRVATSKI ONKOLOŠKI KONGRES 18th CROATIAN ONCOLOGY CONGRESS

27. 03. - 30. 03. 2025.

Rovinj, Hotel Lone

Supplement editors:

Eduard Vrdoljak and Marijana Jazvić

Rovinj, Croatia

March, 2025

ORGANIZER

Hrvatsko onkološko društvo – Hrvatski liječnički zbor
Croatian Society of Oncology

Organizing committee:

President:

Eduard Vrdoljak

Secretaries:

Antonio Juretić, Ingrid Belac Lovasić

Lidija Beketić Orešković, Sestre milosrdnice UHC; Ana Fröbe, Sestre milosrdnice UHC; Višnja Matković, UHC Zagreb; Miroslav Samaržija, UHC Zagreb; Mladen Solarić, UHC Zagreb; Stjepko Pleština, UHC Zagreb; Stipislav Jadrijević, CH Merkur; Nina Dabelić, Sestre milosrdnice UHC; Marijo Boban, UHC Split– Firule; Marko Zelić, UHC Rijeka; Snježana Tomić, UHC Split; Martina Bašić Koretić, UH Dubrava; Josipa Flam, UHC Osijek; Goran Golčić, UHC Rijeka; Marko Jakopović, UHC Zagreb – Jordanovac; Tomislav Omrčen, UHC Split – Firule; Igor Tomašković, Sestre milosrdnice UHC; Mario Šekerija, Croatian National Cancer Registry; Inga Marjanović, UCH Mostar; Branka Petrić Miše, UHC Split; Marijana Jazvić, Sestre milosrdnice UHC; Jasna Radić, Sestre milosrdnice UHC; Ilijan Tomaš, Osijek UHC; Ivana Canjko Osijek UHC

Sponsors and exhibitors:

Abbvie

Amgen

Astellas

AstraZeneca

Bausch Health

Bayer

Ewopharma

Genesis Pharma

GlaxoSmithKline

Johnson & Johnson S.E.

Lilly

Medison Pharma

Merck

Merck Sharp & Dohme

Novartis

Oktal Pharma

Pfizer

Pharmabiz

PharmaS

Roche

Sandoz

Sanolabor

Servier

StargenEU

CONTENTS

ORAL PRESENTATIONS

Jure Murgić, Ana Fröbe	
S1 – Role of comprehensive genome profiling (CGP) in prostate cancer – a precision oncology view	3
Ante Strikić	
S2 – How to treat patients with MCRPC treated with triplet therapy in MHSPC?	5
Milena Gnjidić	
S3 – Treatment of metastatic renal cell carcinoma after progression to first-line therapy	7
Snježana Tomić	
S4 – Liquid biopsy in patients with lung cancer	9
Marijo Boban	
S5 – Optimization of immunotherapy in patients with resectable non-small cell lung cancer	10
Ivana Canjko, Maja Kovač Barić, Mirela Šambić-Penc, Luka Perić, Sebastijan Spajić, Dino Belić, Dominik Seletković, Silva Guljaš, Zdravka Krivdić Dupan	
S6 – Management of patients with brain metastases – an individualized approach	12
Jasna Radić	
S7 – Advances in treatment of small– cell lung cancer	13
Marija Ban	
S8 – Shorter duration of breast cancer radiotherapy?	15
Krešimir Tomić	
S9 – Locoregionally advanced cervical cancer; is there a generally accepted standard of treatment?	17
Kristina Katić	
S10 – Endometrial cancer: the role of precise diagnostics and therapy.	19
Petar Suton	
S11 – New advances in the therapy of head and neck squamous cell carcinoma	21

Vesna Bišof	
S12 – Optimization of advanced gastric cancer treatment in the era of biomarkers	21
Juraj Prejac	
S13 – Young-onset colorectal cancer	23
Majana Soče	
S14 – The role of radiation oncology in the treatment of gastrointestinal cancers	25
Sara Bilić Knežević, Slavica Zubčić Krišto, Mirisa Tokić, Ivana Radovčić Gauta, Vesna Telesmanić Dobrić	
S15 – Case report of a BRCA-2 mutated breast cancer patient	27

POSTER PRESENTATIONS

Davor Kust, Jasmina Marić Brozić, Alma Demirović, Željko Soldić, Jasna Radić, Marin Šunjić, Andrea Burić, Ana Fröbe	
P1 – Anal cancer treatment outcomes: a single center experience	31
Vid Duplančić, Katarina Boko, Jelena Šuto Pavičić, Dora Čerina Pavlinović, Katarina Leko, Petra Lepetić, Petra Linarić, Nikolina Lonjak, Ana Bobinac, Luka Vončina, Robert Šeparović, Eduard Vrdoljak	
P2 – Assessing work productivity and return-to-work outcomes among breast cancer patients: a study across two healthcare institutions	32
Mirela Kekić, Jure Murgić, Marijana Jazvić, Angela Prgomet Sečan, Marija Gamulin, Milena Gnjidić, Sanja Vušković, Tomislav Omrčen, Dag Zahirović, Mirela Šambić Penc, Maja Drežnjak Madunić, Ivo Dilber, Slavica Zubčić Krišto, Mihaela Trajbar, Ljubica Vazdar, Lana Jajac Bručić, Anuška Budisavljević, Antonija Salamun, Zvonko Curić, Iva Kardum Fucak, Anamarija Kovač Peić, Zvezdana Borić-Mikez, Ana Fröbe	
P3 – Avelumab as maintenance after platinum-based chemotherapy for advanced urothelial cancer (aUC) – fourth update from Croatian Uro-Oncology Collaborative Group (CUOCG)	34
Maja Erceg Tušek, Ljiljana Vukota	
P4 – Beyond survival: my survivorship plan – what works for me?	35
Niko Dunkić, Darijo Hrepić, Matea Jakas Vučić, Marica Barać, Zvonimir Družianić, Vid Duplančić, Katarina Boko, Jelena Šuto Pavičić, Dora Čerina Pavlinović, Eduard Vrdoljak	
P5 – Characteristics and outcomes of untreated metastatic colorectal cancer patients: a single center experience	37
Irma Stilinović, Petar Suton, Martina Bašić Koretić, Višnja Gregov, Antonio Juretić, Mitar Mia Mihaljević, Mirna Ravlić, Ana Roguljić Guteša	
P6 – Comprehensive genomic profiling (CGP): single tertiary center experience	38
Dora Čerina Pavlinović, Branka Petrič Miše, Ivana Tica Sedlar, Marija Pancirov, Jelena Šuto Pavičić, Katarina Boko, Vid Duplančić, Eduard Vrdoljak	
P7 – Comprehensive genomic profiling guided therapy in the treatment of gynecological cancers – results from the department of radiotherapy and oncology; UHC Split	40

Slaven Stanojlović, Dora Gudelj, Viktor Šabarić, Luka Simetić, Davorin Herceg, Lea Galunić Bilić	
P8 – Correlation of radiologic and pathologic response after neoadjuvant radiotherapy in soft tissue sarcoma: a single-institution retrospective analysis	41
Zdravka Krivdić Dupan, Ivana Canjko, Mirela Šambić Penc, Tomislav Jovanić, Sebastijan Spajić, Tara Cvijić, Dino Belić, Luka Perić, Marta Biljan, Ingrid Prlić Seršić, Karla Šutalo	
P9 – Current evidence for a lung cancer screening program in UHC Osijek	42
Tara Cvijić Perić, Josipa Flam, Ilijan Tomaš, Kristina Kralik, Mirela Šambić Penc, Ivana Canjko, Zdravka Krivdić Dupan, Sebastijan Spajić, Dominik Seletković, Darko Kotromanović, Luka Perić, Laura Zahirović, Vedrana Pavlović, Suzana Mimica, Ines Bilić-Ćurčić	
P10 – Differences in treatment outcomes and incidence of immunotherapy-mediated adverse events between patients with proximal versus distal colorectal cancer	44
Slavica Zubčić Krišto, Sara Bilić Knežević, Željko Raspović, Ivana Radovčić Gauta, Ivan Zrilić, Ivo Dilber, Mirisa Tokić, Vesna Telesmanić Dobrić	
P11 – Effectiveness of the use of cold caps in preventing chemotherapy-induced alopecia – initial experiences from the department of oncology and radiotherapy at Zadar General Hospital	45
Mirela Kekić, Jure Murgić, Marijana Jazvić, Angela Prgomet Sečan, Marija Gamulin, Milena Gnjidić, Sanja Vušković, Tomislav Omrčen, Dag Zahirović, Mirela Šambić Penc, Maja Drežnjak Madunić, Ana Fröbe	
P12 – Enfortumab vedotin (EV) in patients with advanced urothelial carcinoma (aUC) – first results of the Croatian uro-oncology network (CUOCG).	47
Zvonimir Družianić, Dora Čerina Pavlinović, Jelena Šuto Pavičić, Vid Duplančić, Katarina Boko, Niko Dunkić, Marica Barač, Matea Jakas Vučić, Darijo Hrepić, Eduard Vrdoljak	
P13 – Frequency of molecular profiling in metastatic colorectal cancer and its impact on outcomes: a 2022 single-institution status report and comparison with the 2017 data	49
Jelena Šuto Pavičić, Ana Marušić, Ivan Buljan	
P14 – How understandable is oncological information? Linguistic analysis of plain language summaries and corresponding scientific summaries of Cochrane Systematic Reviews about oncology interventions	51
Vid Duplančić, Katarina Boko, Jelena Šuto Pavičić, Dora Čerina Pavlinović, Katarina Leko, Petra Lepetić, Petra Linarić, Nikolina Lonjak, Ana Bobinac, Luka Vončina, Robert Šeparović, Eduard Vrdoljak	
P15 – Investigating breast cancer-specific quality of life in patients from two healthcare settings	52
Hrvoje Brčić, Matea Lekić, Klara Brčić, Neva Purgar Levarda, Kristina Urch, Petra Radić, Jasna Radić, Jasmina Marić Brozić, Ana Fröbe	
P16 – Long-term outcomes in patients with metastatic non-small cell lung cancer who completed 2 years of immunotherapy or chemoimmunotherapy. A single- center experience.	54

Tin Rosan, Ana-Marija Đaković, Sanja Vušković, Tena Mlinarić Koprivanac, Maja Baučić, Vesna Bišof, Tomislav Kuliš, Željko Kaštelan, Marijana Ćorić, Dražen Huić, Marija Gamulin	
P17 – Multimodal treatment of oligometastatic prostate cancer – an individual institution experience	55
Marica Barać, Darijo Hrepić, Matea Jakas Vučić, Niko Dunkić, Zvonimir Družianić, Vid Duplančić, Katarina Boko, Jelena Šuto Pavičić, Dora Čerina Pavlinović, Eduard Vrdoljak	
P18 – Outcomes of treatment based on primary tumour location in patients with metastatic colorectal cancer at the department of oncology and radiotherapy split; diagnosed before and after the COVID-19 pandemic outbreak.	56
Vid Duplančić, Katarina Boko, Jelena Šuto Pavičić, Dora Čerina Pavlinović, Katarina Leko, Petra Lepetić, Petra Linarić, Nikolina Lonjak, Ana Bobinac, Luka Vončina, Robert Šeparović, Eduard Vrdoljak	
P19 – Overall quality of life of breast cancer patients in Croatia: insights from two healthcare institutions.	58
Vesna Bišof, Zoran Rakušić, Sanja Vušković, Darko Kotromanović, Suzana Erić, Jelena Viculin, Ljubica Vazdar, Marin Prpić, Davor Kust, Damir Vučinić	
P20 – Platinum-based chemotherapy plus cetuximab in first-line treatment of recurrent and/or metastatic squamous cell head and neck cancer – a real-world observational study	59
Silva Guljaš, Zdravka Krivdić Dupan, Tamer Salha, Petra Šmit Takač, Mirela Šambić Penc, Ivana Canjko, Karla Šutalo	
P21 – Prostate cancer and prostatic intraepithelial neoplasia-the role of radiologist. . .	61
Dora Gudelj, Slaven Stanojlović, Krešimir Blažičević, Fedor Šantek, Lea Galunić Bilić	
P22 – Radiotherapy for localized soft tissue sarcoma: a single-institution retrospective analysis	63
Krešimir Tomić, Emir Begagić, Ema Voloder, Maja Pezer Naletilić, Gordana Berić Jozić, Sanda Čale, Marija Perić, Dragana Miletić, Lejla Abaza, Dragana Karan Križanac, Nermina Ibišević, Kristina Galić, Inga Marijanović, Semir Vranić, Eduard Vrdoljak	
P23 – Real-world outcomes of treatment for extensive-stage small cell lung cancer: findings from a single-center study from Bosnia and Herzegovina	64
Slaven Stanojlović, Sanja Vušković, Magdalena Petrovčić Kafadar, Majana Soče, Vesna Bišof	
P24 – Recurrent squamous cell carcinoma of the head and neck: a single-institution experience.	65
Dora Čerina Pavlinović, Jelena Šuto Pavičić, Katarina Boko, Vid Duplančić, Eduard Vrdoljak	
P25 – Results of the comprehensive genomic profiling guided therapy – a single institution analysis	66
Katarina Boko, Dora Čerina Pavlinović, Jelena Šuto Pavičić, Vid Duplančić, Eduard Vrdoljak	
P26 – Single-center real-world outcomes on the efficacy of chemotherapy after progression during parpi in GBRCA-positive ovarian cancer.	68

Vid Duplančić, Katarina Boko, Jelena Šuto Pavičić, Dora Čerina Pavlinović, Katarina Leko, Petra Lepetić, Petra Linarić, Nikolina Lonjak, Ana Bobinac, Luka Vončina, Robert Šeparović, Eduard Vrdoljak	
P27 – The extent of informal care provision for breast cancer patients: a study across two croatian healthcare institutions	69
Jelena Šuto Pavičić, Jelena Viculin, Andrija Katić, Matea Buljubašić Franić, Dora Čerina Pavlinović, Katarina Boko, Vid Duplančić, Eduard Vrdoljak	
P28 – The first-line pembrolizumab monotherapy and pembrolizumab-chemotherapy combination for the management of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): single institution experience	70
Jelena Šuto Pavičić, Tomislav Omrčen, Katarina Boko, Dora Čerina Pavlinović, Vid Duplančić, Eduard Vrdoljak	
P29 – The use of adjuvant pembrolizumab in clear cell renal cell carcinoma (ccRCC): single institution experience	72
Matea Jakas Vučić, Darijo Hrepić, Jelena Šuto Pavičić, Dora Čerina Pavlinović, Vid Duplančić, Katarina Boko, Marica Barač, Niko Dunkić, Zvonimir Družianić, Eduard Vrdoljak	
P30 – THE use of pembrolizumab in microsatellite instability-high colorectal cancer: a single-center experience from Croatia	73
Niko Dunkić, Darijo Hrepić, Matea Jakas Vučić, Marica Barač, Zvonimir Družianić, Vid Duplančić, Katarina Boko, Jelena Šuto Pavičić, Dora Čerina Pavlinović, Eduard Vrdoljak	
P31 – Treatment options for metastatic colorectal carcinoma in patients aged ≥70 years	74
Sebastijan Spajić ^{1,2} , Ivana Canjko ¹ , Luka Perić ^{1,2} , Dino Belić ^{1,2} , Tara Cvijić Perić ^{1,2} , Tatjana Ladenhauser ¹ , Zdravka Krivdić Dupan ^{1,3} , Ilijan Tomaš ^{1,2}	
P32 – Treatment outcomes of patients with metastatic non-small cell lung cancer treated with atezolizumab – a single center experience	76
Damir Grebić, Tamara Gulić, Sara Bilić Knežević	
P33 – Upregulation of metallothionein in triple negative breast cancer	77
Jelena Šuto Pavičić, Ana Marušić, Ivan Buljan	
P34 – Using artificial intelligence chatbot to improve the presentation of plain language summaries: cross-sectional study	78
Sebastijan Spajić, Ivana Canjko, Luka Perić, Dino Belić, Tara Cvijić Perić, Tatjana Ladenhauser, Zdravka Krivdić Dupan, Ilijan Tomaš	
P35 – Treatment outcomes of patients with metastatic non-small cell lung cancer treated with atezolizumab – a single center experience	79
AUTHOR INDEX	81